| Fundamental Mechanisms of Immune Checkpoint Blockade Therapy |
398 |
| STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma |
211 |
| Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts |
120 |
| The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression |
113 |
| IL1-Induced JAK/STAT Signaling Is Antagonized by TGF beta to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma |
112 |
| Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia |
111 |
| Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment |
106 |
| Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer |
105 |
| Tumor Antigen Escape from CAR T-cell Therapy |
98 |
| Integrative Molecular Characterization of Malignant Pleural Mesothelioma |
91 |
| Combined BRAF, EGFR, and MEK Inhibition in Patients with &ITBRAF&ITV600E-Mutant Colorectal Cancer |
87 |
| Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer |
84 |
| CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation |
82 |
| Genetic Mechanisms of Immune Evasion in Colorectal Cancer |
71 |
| Targeting Autophagy in Cancer: Recent Advances and Future Directions |
71 |
| AMG a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies |
70 |
| CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade |
70 |
| BET Proteins as Targets for Anticancer Treatment |
70 |
| Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer |
69 |
| The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial |
69 |
| Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study |
65 |
| Precision Targeted Therapy with BLU-667 for RET-Driven Cancers |
62 |
| Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia |
61 |
| PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer |
59 |
| Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion |
59 |
| Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids |
59 |
| Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibit ROS1/TRK/ALK Solvent-Front Mutations |
55 |
| A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia |
55 |
| Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids |
54 |
| beta-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma |
54 |
| Efficacy of BGJ a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations |
54 |
| Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1(c259) T Cells in Synovial Sarcoma |
53 |
| Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia |
52 |
| SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study |
51 |
| First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study |
51 |
| Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer |
47 |
| Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers |
47 |
| BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma |
45 |
| Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11 |
45 |
| Accelerating Discovery of Functional Mutant Alleles in Cancer |
43 |
| CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment |
43 |
| Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma |
42 |
| Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins |
42 |
| Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases |
42 |
| Genome-Informed Targeted Therapy for Osteosarcoma |
41 |
| Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility |
41 |
| Cellular Plasticity in Cancer |
40 |
| Autophagy Sustains Pancreatic Cancer Growth through Both Cell-Autonomous and nonautonomous Mechanisms |
40 |
| Mouse Models for Cancer Immunotherapy Research |
39 |
| Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer |
39 |
| Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine |
39 |
| TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma |
38 |
| Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates |
38 |
| A Stromal Lysolipid-Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression |
38 |
| Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling into Place |
38 |
| Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models |
37 |
| Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer |
37 |
| Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition |
37 |
| Targeting Alterations in the RAF-MEK Pathway |
37 |
| A First-in-Human Study and Biomarker Analysis of NKTR- a Novel 1L2R beta gamma-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors |
36 |
| Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial |
36 |
| Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy |
32 |
| Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial |
32 |
| PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer |
31 |
| Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene |
31 |
| Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity |
31 |
| Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer |
31 |
| The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector |
29 |
| Acetyl-CoA Metabolism Supports Multistep Pancreatic Tumorigenesis |
29 |
| Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness |
29 |
| SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models |
29 |
| Tumor Neurobiology and the War of Nerves in Cancer |
28 |
| Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers |
28 |
| YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity |
28 |
| TET2 Deficiency Causes Germial Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenes |
28 |
| In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma |
27 |
| Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor |
26 |
| MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and Is Activated through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification |
26 |
| Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors |
26 |
| Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts |
26 |
| Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial |
25 |
| The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells |
25 |
| Naive T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers |
24 |
| Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers |
24 |
| First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma |
24 |
| BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX5 a Novel Structurally Distinct BET Inhibitor |
24 |
| Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis |
24 |
| Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment |
23 |
| Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA |
23 |
| Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition |
22 |
| Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment |
22 |
| Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer |
22 |
| Tissue-Specific Oncogenic Activity of KRAS(A)(146)(T) |
21 |
| An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory factors |
21 |
| NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer |
21 |
| The Phenotypes of Proliferating Glioblastoma Cells Reside on a Single Axis of Variation |
21 |
| Exploiting MCL1 Dependency with Combination MEK+MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer |
21 |
| Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer |
20 |
| Loss of EZH2 Reprograms BCAA Metabolism to Drive Leukemic Transformation |
20 |
| Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression |
20 |
| The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation |
20 |
| First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study |
20 |
| Immunotherapy Resistance by Inflammation-Induced Dedifferentiation |
20 |
| The Biology of m(6)A RNA Methylation in Normal and Malignant Hematopoiesis |
20 |
| Altered RNA Processing in Cancer Pathogenesis and Therapy |
19 |
| Targeting Glioblastoma Stem Cells through Disruption of the Circadian Clock |
19 |
| PTEN Deficiency and AMPK Activation Promote Nutrient Scavenging and Anabolism in Prostate Cancer Cells |
19 |
| Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition |
19 |
| Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma |
18 |
| A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105 |
18 |
| Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor |
18 |
| An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer |
18 |
| MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF NRAS and NF1-Mutant Melanomas |
18 |
| E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer |
18 |
| Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival |
18 |
| CDK6 Antagonizes p53-Induced Responses during Tumorigenesis |
18 |
| Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition |
17 |
| EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer |
17 |
| Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties |
17 |
| PTEN Methylation by NSD2 Controls Cellular Sensitivity to DNA Damage |
17 |
| Glioma Stem Cell-Specific Superenhancer Promotes Polyunsaturated Fatty-Acid Synthesis to Support EGFR Signaling |
17 |
| The Expanding World of N-MYC-Driven Tumors |
17 |
| A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer |
16 |
| The Metabolic Basis of Kidney Cancer |
16 |
| The Clinical Impact of the Genomic Landscape of Mismatch Repair-Deficient Cancers |
15 |
| A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1 |
14 |
| ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma |
14 |
| Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma |
14 |
| In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms |
14 |
| Tissue-Specific Immunoregulation: A Call for Better Understanding of the Immunostat in the Context of Cancer |
13 |
| Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma |
13 |
| A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer |
13 |
| Intertumoral Heterogeneity in SCLC Is Influenced by the Cell Type of Origin |
13 |
| A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAF(V600E)-Mutant Brain Tumor |
13 |
| Multiple Routes to Oncogenesis Are Promoted by the Human Papillomavirus-Host Protein Network |
12 |
| HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development |
12 |
| Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma |
11 |
| MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia |
11 |
| Spatiotemporal Loss of NF1 in Schwann Cell Lineage Leads to Different Types of Cutaneous Neurofibroma Susceptible to Modification by the Hippo Pathway |
11 |
| Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasmas |
11 |
| Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer |
11 |
| Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL |
11 |
| Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma |
10 |
| Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in &ITBRAF&ITV600E Colorectal Cancer |
9 |
| CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation |
9 |
| A Preexisting Rare PIK3CA(E545K) Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling |
9 |
| Colorectal Tumors Require NUAK1 for Protection from Oxidative Stress |
9 |
| Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML |
9 |
| Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis |
9 |
| Conversion of PRPS Hexamer to Monomer by AMPK-Mediated Phosphorylation Inhibits Nucleotide Synthesis in Response to Energy Stress |
9 |
| Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer |
9 |
| Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma |
9 |
| Polyunsaturated Fatty Acids from Astrocytes Activate PPAR gamma Signaling in Cancer Cells to Promote Brain Metastasis |
9 |
| Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents |
8 |
| MACROD2 Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors |
8 |
| Epigenomics and Singe-Cell Sequencing Define a Developmental Hierarchy in Langerhans Cell Histiocytosis |
8 |
| A Mutation in Histone H2B Represents a New Class of Oncogenic Driver |
8 |
| Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis |
8 |
| EIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC |
8 |
| An LKB1-SIK Axis Suppresses Lung Tumor Growth and Controls Differentiation |
8 |
| Precision Prevention and Early Detection of Cancer: Fundamental Principles |
7 |
| Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with Nf1 Knockout in Boundary Cap Cells |
7 |
| Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth |
7 |
| V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer |
7 |
| Innate alpha beta T Cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming |
7 |
| Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy |
7 |
| Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer |
7 |
| Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ER alpha(WT) and ER alpha(MUT) Breast Cancer |
7 |
| FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor |
6 |
| Deletion 6q Drives T-cell Leukemia Progression by Ribosome Modulation |
6 |
| BCL6 Evolved to Enable Stress Tolerance in Vertebrates and Is Broadly Required by Cancer Cells to Adapt to Stress |
6 |
| The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC |
6 |
| NF-kappa B-Dependent Lymphoid Enhancer Co-option Promotes Renal Carcinoma Metastasis |
6 |
| Pathobiological Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes |
4 |
| Engineering Multidimensional Evolutionary Forces to Combat Cancer |
4 |
| Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer |
4 |
| ADAMDEC1 Maintains a Growth Factor Signaling Loop in Cancer Stem Cells |
4 |
| Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23 |
3 |
| Antitumor T-cell Homeostatic Activation Is Uncoupled from Homeostatic Inhibition by Checkpoint Blockade |
3 |
| GATA3-Controlled Nucleosome Eviction Drives MYC Enhancer Activity in T-cell Development and Leukemia |
3 |
| Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene-Driven Myeloid Leukemia |
3 |
| Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer |
3 |
| A Recurrent Activating Missense Mutation in Waldenstrom Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation |
3 |
| Genomics and Targeted Therapies in Gastroesophageal Adenocarcinoma |
2 |
